Of 656 patients with ALL (all types) diagnosed in Switzerland during 4 consecutive 4-year periods (1976-1979,1980-1983,19841987,1988-1991), 507 were officially registered on protocols ( « study » patients) while 149 were not ( « nonstudy » patients).
The mean incidence of 3.8/100,000 children<15 years/year is higher than reported for other Western countries.
Evidence is presented suggesting that the 656 patients represent only approximately 90% of all children with ALL residing in Switzerland, indicating that the true incidence of ALL might even be higher.
The fraction of « nonstudy
» patients fell from 40% (1976-1979) to 15% (1984-1987).
The rate of survival at 4 years of all patients with ALL ( « study » and « nonstudy ») increased by 17% during the three consecutive periods 1976-1979,1980-1983, and 1984-1987.
As expected, a higher increase (20%) was observed in « study » patients and a statistically nonsignificant lower one (10%) in « nonstudy » patients. 1995 Wiley-Liss, Inc.
Mots-clés Pascal : Leucémie lymphoblastique, Incidence, Epidémiologie, Traitement, Pronostic, Suisse, Europe, Enfant, Homme, Aigu, Hémopathie maligne, Lymphoprolifératif syndrome
Mots-clés Pascal anglais : Acute lymphocytic leukemia, Incidence, Epidemiology, Treatment, Prognosis, Switzerland, Europe, Child, Human, Acute, Malignant hemopathy, Lymphoproliferative syndrome
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 95-0437408
Code Inist : 002B19B. Création : 01/03/1996.